PARPi, which are widely used to treat breast and ovarian cancers carrying BRCA mutations, are now emerging as novel therapeutics for acute leukemia with selected genetic backgrounds; for example, they are effective against IDH1/2- or AML1-ETO-mutant AML cells (Figure 2). The gene discussed is RUNX1; the disease is ovarian carcinoma.